Designation of Canakinumab (Ilaris) as an Orphan Drug - Novartis Pharmaceuticals Australia Pty Limited

Administered by Department of Health, Disability and Ageing

Legislation au C2013G00653 In force Gazette

Legislation content

DESIGNATION OF Canakinumab (ILARIS) AS AN ORPHAN DRUG

 

I, Dr Anthony Gill, Delegate of the Secretary for the purposes of 16J of the Therapeutic Goods Regulations 1990 (“the Regulations”), acting under subregulation 16J(2) of the Regulations, designate Canakinumab (ILARIS) as an orphan drug on 11 April 2013 for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients aged 2 years and older.

 

 

The dose form of Canakinumab (ILARIS) for this indication is Powder for Injection.

 

The sponsor of Canakinumab (ILARIS) is Novartis Pharmaceuticals Australia Pty Limited.

 

 

 

 

 

 

(Signed by)

 

Dr Anthony Gill

Delegate of the Secretary

 

11 April 2013

 

 

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.